BioCentury | Jun 8, 2018
Financial News

Vericel prices $75M follow-on

...cells cultured with mouse fibroblasts and bovine serum, to treat severe burns. In 2016, Vericel's ixmyelocel-T...
BioCentury | Jun 1, 2018
Financial News

Vericel raises $65M in upsized follow-on

...cells cultured with mouse fibroblasts and bovine serum, to treat severe burns. In 2016, Vericel's ixmyelocel-T...
...bone marrow containing adult stem and progenitor cells. Paul Bonanos Epicel (Brand), Epicel (Other) Expanded autologous mixed cell therapy, ixmyelocel-t (cardiac repair cells (crcs), tissue repair cells, vascular repair cells) MACI Vericel...
BioCentury | Jul 27, 2017
Strategy

FDA’s regeneration

...using NIKS human keratinocytes Deep partial thickness burns Phase III May 10 Vericel Corp. (NASDAQ:VCEL) Ixmyelocel-T...
BioCentury | May 19, 2017
Company News

ICT gets rights to Vericel programs in Asia, including China

...licensed portfolio includes cartilage repair drugs Carticel and MACI , burn drug Epicel , and ixmyelocel-T...
...NASDAQ:VCEL), Cambridge, Mass. Innovative Cellular Therapeutics Co. Ltd. , Shanghai, China Business: Musculoskeletal, Dermatology, Cardiovascular Shannon Lehnbeuter Carticel Epicel ixmyelocel-T macimorelin...
BioCentury | Mar 21, 2016
Clinical News

Ixmyelocel-T: Phase IIb data

...heart failure due to ischemic DCM showed that 12-20 transendocardial catheter-based injections of 0.4 mL ixmyelocel-T...
...Vericel Corp. (NASDAQ:VCEL), Cambridge, Mass. Product: Ixmyelocel-T ( Expanded autologous mixed cell therapy ) (formerly Vascular repair cells , Tissue repair cells , Cardiac Repair Cells (CRCs)...
BioCentury | Mar 11, 2016
Clinical News

Vericel cell therapy meets in heart failure trial

...Vericel Corp. (NASDAQ:VCEL) jumped $1.83 (86%) to $3.95 on Thursday after it said cell therapy ixmyelocel-T...
...to treat heart failure due to ischemic dilated cardiomyopathy (DCM). Specifically, trans-endocardial catheter-based injections of ixmyelocel-T...
...decompensated heart failure. Vericel said the incidence of adverse events was comparable between the trial's ixmyelocel-T...
BioCentury | Feb 9, 2015
Clinical News

Ixmyelocel-T: Completed Phase IIb enrollment

...0.4 mL ixmyelocel-T into the left ventricle. Vericel Corp. (NASDAQ:VCEL), Cambridge, Mass. Product: Ixmyelocel-T ( Expanded autologous mixed cell therapy...
...Vericel Corp. (NASDAQ:VCEL), Cambridge, Mass. Product: Ixmyelocel-T ( Expanded autologous mixed cell therapy ) (formerly Vascular repair cells , Tissue repair cells , Cardiac Repair Cells (CRCs)...
BioCentury | Apr 14, 2014
Clinical News

Ixmyelocel-T: Phase IIb ongoing

...an independent DSMB recommended continuation of the double-blind, placebo-controlled, U.S. Phase IIb ixCELL-DCM trial of ixmyelocel-T...
...review of unblinded safety data. ixCELL-DCM is evaluating 12-20 catheter-based intramyocardial injections of 0.4 mL ixmyelocel-T...
...Inc. (NASDAQ:ASTM), Ann Arbor, Mich. Product: Ixmyelocel-T ( Expanded autologous mixed cell therapy ) (formerly Vascular repair cells , Tissue repair cells , Cardiac Repair Cells (CRCs)...
BioCentury | Apr 1, 2013
Finance

1Q Stock Wrap-Up: Out fast at opening bell

...ixmyelocel-T to treat critical limb ischemia (CLI) after terminating the Phase III REVIVE trial of ixmyelocel-T...
...Aastrom Biosciences Inc. (NASDAQ:ASTM) 50% to ~36 $13.6 0.40 12/31/12 $33.8 Discontinuing autologous cell therapy ixmyelocel-T...
BioCentury | Apr 1, 2013
Analyst Picks & Changes

Analyst picks & changes

...his target to $0.25 from $1.65 after Aastrom announced it will no longer develop its ixmyelocel-T...
...for dilated cardiomyopathy (DCM) (see B23). Aastrom, which terminated the Phase III REVIVE trial of ixmyelocel-T...
...part to slow enrollment, said DCM and other rare diseases may require smaller studies for ixmyelocel-T...
Items per page:
1 - 10 of 85